Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging
|ClinicalTrials.gov Identifier: NCT00592982|
Recruitment Status : Completed
First Posted : January 14, 2008
Last Update Posted : October 25, 2013
- Bisphosphonate-associated osteonecrosis of the jaw(ONJ)is detectable by positron emission tomography(PET).
- Bisphosphonate-associated ONJ can be diagnosed and characteristically differentiated from other bony pathologies of the jaw(osteomyelitis, osteolytic lesions, and osteoradionecrosis)by PET imaging.
|Condition or disease|
|Bisphosphonate-associated ONJ Osteomyelitis of the Jaw Osteolytic Lesions of the Jaw Osteoradionecrosis of the Jaw|
Is to review medical records of approximately 1000 patients with bisphosphonate-associated ONJ who have had PET imaging at the time of diagnosis. Also to review medical records of patients who have been diagnosed with jaw osteomyelitis, osteoradionecrosis, and cancerous lytic lesions who received PET imaging at the time of diagnosis.
If sufficient information regarding presentation and treatment cannot be obtained form the medical record, approximately 300 patients will contacted by mail (and phone if necessary) by the PI or sub-investigators to question them regarding the onset of symptoms, treatment interventions, and outcomes.
|Study Type :||Observational|
|Actual Enrollment :||25 participants|
|Official Title:||Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging|
|Study Start Date :||October 2006|
|Primary Completion Date :||August 2013|
|Study Completion Date :||August 2013|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00592982
|United States, Arkansas|
|University of Arkansas for Medical Sciences|
|Little Rock, Arkansas, United States, 72205|
|Principal Investigator:||Brendan Stack, MD||University of Arkansas|